PRPH (ProPhase Labs) Shiller PE Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ProPhase Labs Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProPhase Labs  (OTCPK:PRPH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ProPhase Labs Shiller PE Ratio Related Terms


ProPhase Labs Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Shiller PE Ratio Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.51 35.93 25.81 0.00 0.00

ProPhase Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PRPH vs IDTA, NSTM, NOTVQ: Shiller PE Ratio Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Shiller PE Ratio falls into.



ProPhase Labs Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ProPhase Labs's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, ProPhase Labs's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.22/333.9520*333.9520
=-0.220

Current CPI (Jun. 2026) = 333.9520.

ProPhase Labs Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 0.100 241.428 0.138
201612 -0.400 241.432 -0.553
201703 24.700 243.801 33.833
201706 -1.400 244.955 -1.909
201709 -0.500 246.819 -0.677
201712 1.600 246.524 2.167
201803 0.038 249.554 0.051
201806 -0.200 251.989 -0.265
201809 -0.900 252.439 -1.191
201812 -0.400 251.233 -0.532
201903 -0.900 254.202 -1.182
201906 -1.100 256.143 -1.434
201909 -0.400 256.759 -0.520
201912 -0.400 256.974 -0.520
202003 -0.700 258.115 -0.906
202006 0.100 257.797 0.130
202009 -0.400 260.280 -0.513
202012 -0.800 260.474 -1.026
202103 0.600 264.877 0.756
202106 -0.900 271.696 -1.106
202109 -2.600 274.310 -3.165
202112 7.000 278.802 8.385
202203 6.800 287.504 7.899
202206 4.000 296.311 4.508
202209 0.600 296.808 0.675
202212 -1.600 296.797 -1.800
202303 0.300 301.836 0.332
202306 -2.000 305.109 -2.189
202309 -3.000 307.789 -3.255
202312 -5.100 306.746 -5.552
202403 -3.600 312.332 -3.849
202406 -3.300 314.175 -3.508
202409 -3.500 315.301 -3.707
202412 -16.480 315.605 -17.438
202503 1.130 319.799 1.180
202506 -1.080 322.561 -1.118
202509 -1.600 324.800 -1.645
202512 -0.825 324.054 -0.850
202603 -0.420 330.213 -0.425
202606 -0.220 333.952 -0.220

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.